IVVD

Invivyd, Inc.

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Invivyd, Inc. (IVVD) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Momentum (C-). The rating has held at C+ for 13 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
C-
Factor Score 1.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.1
EV / EBITDA -0.2
Rev Growth YoY 21.2%
Gross Margin 92.2%
Price Return 3M -12.7%
Price Return 12M -62.8%
Catalyst Signal 0.00
Market Cap $176.6M
TTM Revenue $58.4M
Price / Sales 3.0
ROE -95.9%

Historical Factor Score Progression

Held C+ for 13 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B- (3.0) C+ (2.6) B- (3.1) C- (1.9) C+ (2.6) C+ (2.6)
2026-11-05 B- (3.0) C+ (2.6) B- (3.1) C- (2.1) C+ (2.7) C+ (2.7)
2026-10-29 B- (3.0) C+ (2.6) B (3.3) C (2.2) C+ (2.7) C+ (2.8)
2026-10-22 B- (3.0) C+ (2.6) B (3.3) C (2.2) C+ (2.6) C+ (2.7)
2026-10-15 B- (3.0) C+ (2.6) B (3.3) D+ (1.6) C+ (2.6) C+ (2.6)
Page 1 of 5